The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life

被引:38
|
作者
Raluy-Callado, Mireia [1 ]
Chen, Wen-Hung [2 ]
Whiteman, David A. H. [3 ]
Fang, Juanzhi [3 ]
Wiklund, Ingela [1 ]
机构
[1] Evidera, London W6 7HA, England
[2] Evidera, Bethesda, MD 20814 USA
[3] Shire HGT, Lexington, MA 02421 USA
来源
ORPHANET JOURNAL OF RARE DISEASES | 2013年 / 8卷
关键词
Hunter syndrome; Mucopolysaccharidosis type II; Lysosomal storage disease; Patient-reported outcomes; Health-related quality of life; ENZYME REPLACEMENT THERAPY; NATURAL-HISTORY; CHILDREN; QUESTIONNAIRE; IDURSULFASE; FORM;
D O I
10.1186/1750-1172-8-101
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Hunter syndrome (mucopolysaccharidosis type II (MPS II)) is a rare metabolic disease that can severely compromise health, well-being and life expectancy. Little evidence has been published on the impact of MPS II on health-related quality of life (HRQL). The objective of this study was to describe this impact using the Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) questionnaire and a range of standard validated questionnaires previously used in paediatric populations. Methods: Clinical and demographic characteristics collected in a clinical trial and responses to four HRQL questionnaires completed both by patients and parents prior to enzyme replacement treatment were used. The association between questionnaire scores and clinical function parameters were tested using Spearman rank-order correlations. Results were compared to scores in other paediatric populations with chronic conditions obtained through a targeted literature search of published studies. Results: Overall, 96 male patients with MPS II and their parents were enrolled in the trial. All parents completed the questionnaires and 53 patients above 12 years old also completed the self-reported versions. Parents' and patients' responses were analysed separately and results were very similar. Dysfunction according to the HS-FOCUS and the CHAQ was most pronounced in the physical function domains. Very low scores were reported in the Self Esteem and Family Cohesion domains in the CHQ and HUI3 disutility values indicated a moderate impact. Scores reported by patients and their parents were consistently lower than scores in the other paediatric populations identified (except the parent-reported Behaviour score); and considerably lower than normative values. Conclusions: This study describes the impact on HRQL in patients with MPS II and provides a broader context by comparing it with that of other chronic paediatric diseases. Physical function and the ability to perform day-to-day activities were the most affected areas and a considerable impact on the psychological aspects of patients' HRQL was also found, with a higher level of impairment across most dimensions (particularly Pain and Self Esteem) than that of other paediatric populations. Such humanistic data provide increasingly important support for establishing priorities for health care spending, and as a component of health economic analysis.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
    Mireia Raluy-Callado
    Wen-Hung Chen
    David A H Whiteman
    Juanzhi Fang
    Ingela Wiklund
    Orphanet Journal of Rare Diseases, 8
  • [2] Mucopolysaccharidosis Type II, Hunter's Syndrome
    Tylki-Szymanska, Anna
    PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2014, 12 : 107 - 113
  • [3] Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment
    Beck, Michael
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (06) : 861 - 866
  • [4] Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
    Zuber, Zbigniew
    Kiec-Wilk, Beata
    Kaluzny, Lukasz
    Wierzba, Jolanta
    Tylki-Szymanska, Anna
    BIOMEDICINES, 2023, 11 (06)
  • [5] Health-Related Quality of Life in Patients with MPS II
    Needham, Mary
    Packman, Wendy
    Quinn, Natasha
    Rappoport, Maxwell
    Aoki, Christa
    Bostrom, Alan
    Cordova, Matthew
    Macias, Sandra
    Morgan, Cynthia
    Packman, Seymour
    JOURNAL OF GENETIC COUNSELING, 2015, 24 (04) : 635 - 644
  • [6] Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review
    Bradley, Linda A.
    Haddow, Hamish R. M.
    Palomaki, Glenn E.
    GENETICS IN MEDICINE, 2017, 19 (11) : 1187 - 1201
  • [7] Successful Desensitization to Idursulfase in a Patient with Type II Mucopolysaccharidosis (Hunter syndrome)
    Serrano, C. D.
    Gomez, J. F.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2011, 21 (07) : 571 - 572
  • [8] Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues
    Hendriksz, Christian J.
    Berger, Kenneth I.
    Lampe, Christina
    Kircher, Susanne G.
    Orchard, Paul J.
    Southall, Rebecca
    Long, Sarah
    Sande, Stephen
    Gold, Jeffrey I.
    ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [9] Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
    Cho, Sung Yoon
    Huh, Rimm
    Chang, Mi Sun
    Lee, Jieun
    Kwun, Younghee
    Maeng, Se Hyun
    Kim, Su Jin
    Sohn, Young Bae
    Park, Sung Won
    Kwon, Eun-Kyung
    Han, Sun Ju
    Jung, Jooyoun
    Jin, Dong-Kyu
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, 29 (02) : 254 - 260
  • [10] Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
    Yamanishi, Ryutaro
    Nakamura, Natsuko
    Tsunoda, Kazushige
    CASE REPORTS IN OPHTHALMOLOGY, 2019, 10 (02): : 186 - 194